DEF 14A: Teva Pharmaceutical Outlines Growth Strategy and Board Nominees in Proxy Statement

Teva Pharmaceutical's proxy statement highlights the company's 'Pivot to Growth' strategy, board refreshment, and key proposals for the 2024 annual meeting.

Summary

• Teva Pharmaceutical Industries Limited's proxy statement details the agenda for the 2024 Annual Meeting of Shareholders, including the election of directors, an advisory vote on executive compensation, and the appointment of an independent accounting firm.
• The company's 'Pivot to Growth' strategy, introduced in May 2023, focuses on growth engines, innovation, generics, and business optimization.
• Key innovative medicines like AUSTEDO and AJOVY showed promise, with AUSTEDO revenues reaching $1.225 billion in 2023.
• The generics business has stabilized and returned to revenue growth.
• Teva is divesting its API business to focus on core strengths and growth engines.
• The company has reduced net debt by more than $17 billion in the past seven years, with net debt at $16.6 billion as of December 31, 2023.
• The Board of Directors has been refreshed with three new directors in the last four years and emphasizes diversity and inclusion.
• Teva is committed to sustainability, aiming for net-zero greenhouse gas emissions by 2045 and expanding access to medicines in lowand middle-income countries.
• The company is facing adversity in its headquarters in Israel due to the ongoing war.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive achievements and ongoing challenges. The 'Pivot to Growth' strategy and debt reduction efforts are encouraging, but the war in Israel and Say-on-Pay vote results temper the overall sentiment.

Positives

• AUSTEDO revenues grew to $1.225 billion in 2023, indicating strong performance in innovative medicines.
• The generics business has returned to revenue growth, contributing to overall financial stability.
• Teva has significantly reduced its net debt, improving its financial position.
• The Board of Directors is actively engaged in refreshment and emphasizes diversity and inclusion.
• The company is committed to sustainability and has set ambitious targets for emissions reduction and access to medicines.
• Teva's collaboration with Sanofi on the anti-TL1A asset provides significant financial and development support.
• The company has a robust biosimilar pipeline with five expected launches by 2027.

Negatives

• The company is facing adversity in its headquarters in Israel due to the ongoing war, creating uncertainties.
• The advisory Say-on-Pay proposal regarding the compensation of our NEOs received the support of approximately 49.6% of the votes cast.

Risks

• The ongoing war in Israel poses uncertainties for the company's operations and employees.
• The company faces risks related to intellectual property and research and development activities.
• Teva is exposed to cybersecurity risks, requiring ongoing management and mitigation efforts.
• The company's success depends on attracting, developing, and retaining top talent in a competitive pharmaceutical industry.
• Teva's ability to achieve its sustainability goals is subject to various factors, including technological advancements and regulatory changes.

Future Outlook

Teva expects continued progress across key innovative growth initiatives, execution on its generics business, and exciting clinical milestones for late-stage pipeline assets in 2024. The roadmap for the Pivot to Growth strategy envisions: in 2023 and 2024, a return to growth based on AUSTEDO, AJOVY and UZEDY; from 2025 to 2027, an acceleration of growth based on launches of new innovative products, growth in biosimilar generics, an optimized generics business and focused business development; and in 2028 and beyond, sustained growth through further launches of innovative products, a sustainable innovative pipeline, additional focused business development and margin expansion.

Management Comments

• Dr. Sol J. Barer, Chairman of the Board, expressed excitement about continued progress across key innovative growth initiatives and executing on the generics business.
• Richard Francis, President and CEO, introduced the new 'Pivot to Growth' strategy based on four key pillars.
• Management is focused on continued value creation powered by ongoing momentum.

Industry Context

Teva's focus on generics and biosimilars aligns with the industry trend of seeking more affordable medicine options, while its investment in innovative medicines reflects the need for novel treatments to address unmet health needs. The company's sustainability initiatives are in line with increasing stakeholder expectations for environmental and social responsibility in the pharmaceutical sector.

Comparison to Industry Standards

• Teva's peer group includes AbbVie, Amgen, Astellas Pharma, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly & Co., Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck KGaA, Novo Nordisk A/S, Sanofi, Takeda Pharmaceutical Co., Ltd., and Viatris, Inc.
• The company benchmarks its executive compensation against these peers to attract and retain talent.
• Teva's sustainability-linked bonds are part of a growing trend in the pharmaceutical industry to tie financing to environmental and social goals.
• The company's focus on generics and biosimilars positions it to compete with companies like Viatris and Sandoz, while its innovative pipeline puts it in competition with companies like AbbVie, Amgen, and Eli Lilly.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings, including the U.S. DOJ patient assistance program litigation, opioid cases, and antitrust charges.

Related Party Transactions

• Teva has collaborative research agreements with Tel Aviv University, where Prof. Ronit Satchi-Fainaro, a member of the Board of Directors, is a professor.

Stakeholder Impact

• The 'Pivot to Growth' strategy aims to improve health outcomes for millions of patients by advancing scientific innovation and ensuring access to quality medicines.
• The company's sustainability initiatives benefit the environment and communities.
• Employees are supported through various programs, including career growth, wellbeing initiatives, and mental health support during the war in Israel.
• Shareholders are expected to benefit from the company's focus on value creation and long-term growth.

Next Steps

• Shareholders will vote on the election of directors, executive compensation, and the appointment of an independent accounting firm at the Annual Meeting on June 6, 2024.
• Teva will continue to implement its 'Pivot to Growth' strategy and focus on achieving its financial and sustainability goals.
• The company will continue to monitor the situation in Israel and provide support to its employees and communities.

Key Dates

Keywords

Teva Pharmaceutical, Proxy Statement, Growth Strategy, Board of Directors, Executive Compensation, AUSTEDO, AJOVY, Generics, Biosimilars, Sustainability, Net Debt, Innovation, API Business, Sanofi, Olanzapine LAI